CTIC CTI BioPharma Corporation

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant:  ☒

Filed by a Party other than the Registrant:  ☐

Check the appropriate box:

CTI BioPharma Corp.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of filing fee (Check all boxes that apply):

You invested in CTI BIOPHARMA CORP. and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 21, 2023.

Get informed before you vote

View the Notice, Proxy Statement and 2022 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 7, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

*The company will be hosting the meeting live via the Internet this year at the website address above. Please check the proxy materials for instructions on how to access the meeting.

V1.1

 Vote at www.ProxyVote.com

THIS IS NOT A VOTABLE BALLOT

Voting Items				Board Recommends
1.		To elect directors to the Company’s Board of Directors to serve until the 2024 annual meeting of stockholders.
		Nominees:
1a.		Adam R. Craig, M.D., Ph.D.		For
1b.		Laurent Fischer, M.D.		For
1c.		Michael A. Metzger		For
1d.		David Parkinson, M.D.		For
1e.		Diane Parks		For
1f.		Matthew D. Perry		For
1g.		Reed V. Tuckson, M.D., F.A.C.P.		For
2.		To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm.		For
3.		To approve, by non-binding advisory vote, the compensation of our named executive officers.		For
4.		To conduct a non-binding advisory vote to determine the frequency of holding future advisory votes on executive compensation.		Year
NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the annual meeting or any adjournments and postponements thereof.

V13439-P90671